Analysis of items that require regular inspection during treatment with Mobosetinib (Anvili)

Mobocertinib is a selective oral tyrosine kinase inhibitor (TKI), mainly used to treat patients with non-small cell lung cancer carrying EGFR exon 20 insertion mutations. Due to the special metabolic characteristics and potential side effects of this drug in the body, patients need to undergo a series of regular examinations during the treatment process so that doctors can promptly evaluate the efficacy and safety and achieve early detection and intervention, thereby improving medication compliance and treatment benefits.

Electrocardiogram (ECG) monitoring is one of the core examinations during moboxetinib treatment. Studies have shown that mobosetinib may prolong the QT interval and increase the risk of arrhythmia. Therefore, patients need to have a baseline electrocardiogram before starting medication and regular reexaminations during treatment, especially when other drugs that may affect cardiac conduction are used in combination. If a significant prolongation of the QT interval is detected, the doctor may adjust the dose or temporarily discontinue the drug.

Liver function and renal function monitoring It is also very important. Mobosetinib is metabolized by the liver, and some metabolites are excreted by the kidneys, so it may impose a certain burden on liver and kidney function. It is recommended that patients test serum aminotransferase, bilirubin and creatinine levels before taking the drug and review them regularly during treatment. Once significant abnormalities in indicators are found, dose reduction or discontinuation should be considered, and corresponding supportive treatment should be given.

Electrolyte levels (such as potassium, magnesium, calcium) and routine blood tests also need to be tested regularly. Because hypokalemia and hypomagnesemia may further increase the risk of arrhythmia, routine blood tests can help detect potential bone marrow suppression or other drug-related adverse reactions. By dynamically monitoring these items, doctors can better assess patients' tolerance and safety and ensure that risks during mobosetinib treatment are controllable.

Reference link:https://www.drugs.com